Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

/PRNewswire/ — Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the…Read More